Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Etalanetug, an antibody targeting Tau.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Emugrobart, an antibody targeting ENTPD1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Roledumab, an antibody targeting RhD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Begelomab, an antibody targeting DPP4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Glenzocimab, an antibody targeting GP6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Plonmarlimab, an antibody targeting CSF2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Anbenitamab, an antibody targeting HER2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vobramitamab, an antibody targeting B7-H3.

2026 Metaplastic breast cancer strategy: epidemiology, EGFR biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Male breast cancer strategy: epidemiology, ERα biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…

2026 Inflammatory breast cancer strategy: epidemiology, HER2 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Neuroendocrine prostate cancer strategy: epidemiology, DLL3 biology, clinical competition, recent deals, unmet need and market attractiveness.